Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
ImmuPharma ( (GB:IMM) ) has issued an update.
ImmuPharma PLC announced its final results for 2024, highlighting significant advancements in its P140 autoimmune technology platform. The company reported a reduced loss for the period and a successful fundraising effort. Key developments include groundbreaking preclinical research that enhances diagnostics and treatment monitoring for autoimmune diseases, and evidence supporting P140’s unique mechanism of action, which is non-immunosuppressive. These advancements have strengthened ImmuPharma’s intellectual property portfolio and opened discussions with potential global commercial partners, positioning the company for future growth and impact in the autoimmune disease treatment market.
More about ImmuPharma
ImmuPharma PLC is a specialist drug discovery and development company focused on creating innovative therapies for autoimmune diseases. The company’s primary product is the P140 technology platform, which aims to provide novel treatments for conditions such as systemic lupus erythematosus (SLE) by restoring immune system balance.
Average Trading Volume: 3,086,600
Technical Sentiment Signal: Buy
Current Market Cap: £16.77M
See more data about IMM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue